Published in Nicotine Tob Res on April 01, 2008
Conference on abuse liability and appeal of tobacco products: conclusions and recommendations. Drug Alcohol Depend (2011) 1.09
Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy. Pharmacol Ther (2009) 1.04
The changing public image of smoking in the United States: 1964-2014. Cancer Epidemiol Biomarkers Prev (2014) 0.87
Short-term pulmonary effects of using an electronic cigarette: impact on respiratory flow resistance, impedance, and exhaled nitric oxide. Chest (2011) 3.87
Electronic cigarettes: a new 'tobacco' industry? Tob Control (2010) 2.95
Electronic cigarettes: the tobacco industry's latest threat to oral health? J Am Dent Assoc (2015) 2.81
Nicotine reduction revisited: science and future directions. Tob Control (2010) 2.41
Designing cigarettes for women: new findings from the tobacco industry documents. Addiction (2005) 2.40
Patterns of dual use of cigarettes and smokeless tobacco among US males: findings from national surveys. Tob Control (2009) 2.29
New cigarette brands with flavors that appeal to youth: tobacco marketing strategies. Health Aff (Millwood) (2005) 2.22
Eclipse: does it live up to its health claims? Tob Control (2002) 2.08
Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl) (2004) 2.07
A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation. Tob Control (2012) 2.00
The menthol smoker: tobacco industry research on consumer sensory perception of menthol cigarettes and its role in smoking behavior. Nicotine Tob Res (2008) 1.98
Trends in the use of cigarettes and other tobacco products, 2000-2007. JAMA (2008) 1.92
Tobacco industry control of menthol in cigarettes and targeting of adolescents and young adults. Am J Public Health (2008) 1.85
Concern about security and privacy, and perceived control over collection and use of health information are related to withholding of health information from healthcare providers. J Am Med Inform Assoc (2013) 1.82
Measuring air quality to protect children from secondhand smoke in cars. Am J Prev Med (2006) 1.78
The Fagerstrom Test for Nicotine Dependence and the Diagnostic Interview Schedule: do they diagnose the same smokers? Addict Behav (2002) 1.74
Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiol Biomarkers Prev (2009) 1.74
Tobacco harm reduction: conceptual structure and nomenclature for analysis and research. Nicotine Tob Res (2002) 1.72
Youth access, creation, and content of smokeless tobacco ("dip") videos in social media. J Adolesc Health (2011) 1.70
Reducing the nicotine content to make cigarettes less addictive. Tob Control (2013) 1.60
Harm reduction approaches to reducing tobacco-related mortality. Annu Rev Public Health (2004) 1.56
Application, function, and effects of menthol in cigarettes: a survey of tobacco industry documents. Nicotine Tob Res (2004) 1.54
Smokers' responses to advertisements for regular and light cigarettes and potential reduced-exposure tobacco products. Nicotine Tob Res (2004) 1.53
Global surveillance of oral tobacco products: total nicotine, unionised nicotine and tobacco-specific N-nitrosamines. Tob Control (2010) 1.51
Making smoking history worldwide. N Engl J Med (2007) 1.49
Alcohol screening and intervention in trauma centers: confidentiality concerns and legal considerations. J Trauma (2005) 1.49
Negative outcomes of unbalanced opioid policy supported by clinicians, politicians, and the media. J Pain Palliat Care Pharmacother (2016) 1.40
The first decade of the Massachusetts Tobacco Control Program. Public Health Rep (2005) 1.39
The role of sensory perception in the development and targeting of tobacco products. Addiction (2007) 1.35
Storefront cigarette advertising differs by community demographic profile. Am J Health Promot (2010) 1.32
Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example. Cancer Epidemiol Biomarkers Prev (2009) 1.24
Smoke-free air laws and secondhand smoke exposure among nonsmoking youth. Pediatrics (2010) 1.24
The strategic targeting of females by transnational tobacco companies in South Korea following trade liberalization. Global Health (2009) 1.20
Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend (2005) 1.20
Correlation between pharmacological effects and plasma cocaine concentrations after smoked administration. J Anal Toxicol (2002) 1.19
Secondhand smoke exposure and neurobehavioral disorders among children in the United States. Pediatrics (2011) 1.19
Environmental and economic evaluation of the Massachusetts Smoke-Free Workplace Law. J Community Health (2007) 1.17
Understanding worldwide youth attitudes towards smoke-free policies: an analysis of the Global Youth Tobacco Survey. Tob Control (2011) 1.16
Increasing prevalence of smoke-free homes and decreasing rates of sudden infant death syndrome in the United States: an ecological association study. Tob Control (2011) 1.15
Assessing consumer responses to potential reduced-exposure tobacco products: a review of tobacco industry and independent research methods. Cancer Epidemiol Biomarkers Prev (2009) 1.13
Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs (2008) 1.12
Does menthol enhance the addictiveness of cigarettes? An agenda for research. Nicotine Tob Res (2003) 1.12
Characterization of measured menthol in 48 U.S. cigarette sub-brands. Nicotine Tob Res (2005) 1.11
Prevalence and determinants of tobacco use among adults in Greece: 4 year trends. Eur J Public Health (2012) 1.10
Brave new world of tobacco disease prevention: promoting dual tobacco-product use? Am J Prev Med (2002) 1.10
A meta-analysis based on diffuse definitions and mixed quality literature is not a good fundament for decisions on treatment of chronic pain patients. Pain (2015) 1.06
Human cocaine-seeking behavior and its control by drug-associated stimuli in the laboratory. Neuropsychopharmacology (2005) 1.06
Subjective effects of the nicotine lozenge: assessment of abuse liability. Psychopharmacology (Berl) (2003) 1.04
Second-hand smoke levels in Israeli bars, pubs and cafes before and after implementation of smoke-free legislation. Eur J Public Health (2010) 1.03
Temporal trends in smokeless tobacco use among US middle and high school students, 2000-2011. JAMA (2013) 1.02
Assessing internal tobacco industry knowledge of the neurobiology of tobacco dependence. Nicotine Tob Res (2004) 0.99
Cigarette sales in pharmacies in the USA (2005-2009). Tob Control (2011) 0.99
Recent Advances in Cigarette Ignition Propensity Research and Development. Fire Technol (2010) 0.99
Intravenous nicotine reduces cerebral glucose metabolism: a preliminary study. Neuropsychopharmacology (2002) 0.99
Swedish Match marketing on YouTube. Tob Control (2010) 0.99
Prevalence and social environment of cigarette smoking in Cyprus youth. BMC Public Health (2008) 0.99
Smoke-free air laws and asthma prevalence, symptoms, and severity among nonsmoking youth. Pediatrics (2010) 0.98
Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacol Biochem Behav (2002) 0.98
Main determinants of cigarette smoking in youth based on the 2006 Cyprus GYTS. Prev Med (2009) 0.97
Use of conventional and novel smokeless tobacco products among US adolescents. Pediatrics (2013) 0.97
Smoke-free households with children and decreasing rates of paediatric clinical encounters for otitis media in the United States. Tob Control (2011) 0.95
Pharmacotherapy for tobacco dependence. Handb Exp Pharmacol (2009) 0.95
Does switching to reduced ignition propensity cigarettes alter smoking behavior or exposure to tobacco smoke constituents? Nicotine Tob Res (2010) 0.95
Role of cigarette sensory cues in modifying puffing topography. Drug Alcohol Depend (2012) 0.93
Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report. Drug Alcohol Depend (2009) 0.92
Effectiveness of the cigarette ignition propensity standard in preventing unintentional residential fires in Massachusetts. Am J Public Health (2014) 0.91
Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. Drug Alcohol Depend (2006) 0.91
Male tobacco smoke load and non-lung cancer mortality associations in Massachusetts. BMC Cancer (2008) 0.91
Rapid absorption of nicotine from new nicotine gum formulations. Pharmacol Biochem Behav (2008) 0.89
After the master settlement agreement: targeting and exposure of youth to magazine tobacco advertising. Health Aff (Millwood) (2008) 0.89
Tobacco control efforts: where is India now? Lancet (2007) 0.89
Treatment of adolescent tobacco smokers: issues and opportunities for exposure reduction approaches. Drug Alcohol Depend (2003) 0.88
R. J. Reynolds goes international with new dissolvable tobacco products. Tob Control (2011) 0.87
Case histories in pharmaceutical risk management. Drug Alcohol Depend (2009) 0.87
Puffing style and human exposure minimally altered by switching to a carbon-filtered cigarette. Cancer Epidemiol Biomarkers Prev (2008) 0.87
Secondhand smoking, 4-aminobiphenyl, and bladder cancer: two meta-analyses. Cancer Epidemiol Biomarkers Prev (2009) 0.87
Methods used in internal industry clinical trials to assess tobacco risk reduction. Cancer Epidemiol Biomarkers Prev (2009) 0.87
Exposure to different sources of second-hand smoke during pregnancy and its effect on urinary cotinine and tobacco-specific nitrosamine (NNAL) concentrations. Tob Control (2012) 0.87
The role of the non-smoker in enforcing smoke-free laws. J Public Health Policy (2010) 0.87
Recent lung cancer patterns in younger age-cohorts in Ireland. Ulster Med J (2007) 0.86
Indoor secondhand tobacco smoke emission levels in six Lebanese cities. Tob Control (2010) 0.86
Nicotine delivery systems. Expert Opin Drug Deliv (2005) 0.85
Smokers' self-reported responses to the introduction of reduced ignition propensity (RIP) cigarettes. Tob Control (2011) 0.85
Population use, sales, and design: a multidimensional assessment of "light" cigarettes in the United States, 2009. Am J Public Health (2013) 0.84
Industry research on the use and effects of levulinic acid: a case study in cigarette additives. Nicotine Tob Res (2005) 0.84
Introduction to College on Problems of Drug Dependence special conference on risk management and post-marketing surveillance of CNS drugs. Drug Alcohol Depend (2009) 0.84
Declining maternal smoking prevalence did not change low birthweight prevalence in Massachusetts from 1989 to 2004. Eur J Public Health (2008) 0.83
Nursing education and beliefs towards tobacco cessation and control: a cross- sectional national survey (GHPSS) among nursing students in Greece. Tob Induc Dis (2011) 0.82
Reduced lung cancer deaths attributable to decreased tobacco use in Massachusetts. Cancer Causes Control (2007) 0.81
Five-year trends of second-hand smoke exposure in Greece: a comparison between complete, partial, and prelegislation levels. J Aerosol Med Pulm Drug Deliv (2012) 0.81
Tobacco, nicotine, and human cognition. Nicotine Tob Res (2002) 0.81
Serotonergic responsiveness in human cocaine users. Drug Alcohol Depend (2006) 0.81
The impact of the Cyprus comprehensive smoking ban on air quality and economic business of hospitality venues. BMC Public Health (2013) 0.81
Regulating duty free sales and tobacco advertising in airports: a call for action. Tob Induc Dis (2011) 0.81
Exploitation by design-could tobacco industry documents guide more effective smoking prevention and cessation in women? Addiction (2005) 0.81
Coronary heart disease deaths and decreased smoking prevalence in Massachusetts, 1993-2003. Am J Public Health (2008) 0.81
Physical design analysis and mainstream smoke constituent yields of the new potential reduced exposure product, Marlboro UltraSmooth. Nicotine Tob Res (2007) 0.80
Internal tobacco industry research on olfactory and trigeminal nerve response to nicotine and other smoke components. Nicotine Tob Res (2007) 0.80